Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathomorphological Features of Lung Damage Caused by Infection with Various Variants of SARS-CoV-2 in Humanized Model Animals.

Doklady. Biochemistry and biophysics·2026

Same author

Isolation, Purification, and Structural-Functional Analysis of Recombinant Human Transferrin Produced by the Methylotrophic Yeast Strain Pichia pastoris.

Bulletin of experimental biology and medicine·2026

Same author

The Impact of the Intracellular Domains of Chimeric Antigenic Receptors on the Properties of CAR T-cells.

Acta naturae·2025

Same author

Specific Matrix on the Basis of Angiotensin-Converting Enzyme 2: Development and Functional Analysis.

Bulletin of experimental biology and medicine·2025

Same author

Heterologous Production of Antimicrobial Peptides in Yeast Allows for Massive Assessment of the Activity of DNA-Encoded Antimicrobials In Situ.

Acta naturae·2025

Same author

Bacteriocin from the Raccoon Dog Oral Microbiota Inhibits the Growth of Pathogenic Methicillin-Resistant Staphylococcus aureus.

Acta naturae·2025

Same journal

The Microbiomic Metaproteome of the Taiga Tick Ixodes persulcatus from the Tyumen Region.

Acta naturae·2026

Same journal

The Distribution and Genetic Variability of Potato Viruses in Russian Regions.

Acta naturae·2026

Same journal

Stabilization of Transaminases in Aqueous-Organic Media by Pyridoxal-5'-phosphate: A Case Study of Transaminase from Desulfomonile tiedjei.

Acta naturae·2026

Same journal

Novel Nicotinic Acetylcholine Receptor Inhibitors Derived from Oleoylcholine Analogs.

Acta naturae·2026

Same journal

Identifying microRNA Expression Alterations in Erythrocytes, Lymphocytes, and Monocytes During Severe COVID-19.

Acta naturae·2026

Same journal

Cellular Type Is a Major Determinant of R-Loop Genomic Distribution.

Acta naturae·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Published on: October 18, 2024

Neutrophil Extracellular Traps (NETs): Opportunities for Targeted Therapy.

D V Volkov¹, G V Tetz², Y P Rubtsov¹

¹Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, 117997 Russia.

|October 28, 2021

Summary

This summary is machine-generated.

Advanced cancers resist therapy, especially solid tumors, due to the tumor microenvironment (TME). Neutrophil extracellular traps (NETs) in the TME impede CAR-T cell therapy. DNase I may overcome this resistance by degrading NETs.

Keywords:

NETosis cancer neutrophils tumor microenvironment

More Related Videos

Neutrophil Extracellular Traps: How to Generate and Visualize Them

Neutrophil Extracellular Traps: How to Generate and Visualize Them

Published on: February 24, 2010

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Published on: August 3, 2018

Related Experiment Videos

Last Updated: Oct 15, 2025

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists

Published on: October 18, 2024

Neutrophil Extracellular Traps: How to Generate and Visualize Them

Neutrophil Extracellular Traps: How to Generate and Visualize Them

Published on: February 24, 2010

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumor Cell Growth and Attachment

Published on: August 3, 2018

Area of Science:

Immunology
Oncology
Biochemistry

Background:

Adoptive immunotherapy, particularly CAR-T cells, shows promise against hematological malignancies but faces challenges with solid tumors.
The tumor microenvironment (TME) is a key factor in solid tumor resistance to antitumor therapies.
Neutrophils and their extracellular traps (NETs) are increasingly recognized as significant contributors to the immunosuppressive TME and tumor progression.

Purpose of the Study:

To investigate the role of neutrophil extracellular traps (NETs) in mediating resistance of solid tumors to CAR-T cell therapy.
To explore the potential of deoxyribonuclease I (DNase I) as a therapeutic agent to degrade NETs and enhance CAR-T cell efficacy within the TME.
To review current strategies for mitigating the suppressive effects of NETs in the tumor microenvironment.

Main Methods:

Literature review of studies on CAR-T cell therapy, tumor microenvironment, neutrophils, NETs, and DNase I.
Analysis of the mechanisms by which NETs contribute to immune evasion and therapeutic resistance in solid tumors.
Evaluation of preclinical data and proposed therapeutic strategies involving DNase I for NET degradation.

Main Results:

NETs, composed of neutrophil DNA, form a physical barrier hindering CAR-T cell interaction with tumor cells.
The presence of NETs within the TME correlates with tumor development and metastasis.
DNase I has demonstrated potential in degrading NETs, suggesting a strategy to disrupt this barrier.

Conclusions:

NETs represent a significant obstacle for CAR-T cell-based antitumor therapy in solid tumors.
Targeting NETs with agents like DNase I holds promise for improving the effectiveness of adoptive immunotherapies.
Further research into NET-modulating strategies is crucial for advancing cancer treatment.